Loading
companiesCompany
Biocon Biologics
Biocon's biosimilars arm, one of the few companies outside the US and Europe with FDA- and EMA-approved cancer antibody biosimilars, and since 2022 the owner of Viatris's biosimilars business.
Overview
Biocon Biologics was set up in 2000 as Biocon's biosimilar subsidiary and became a wholly owned, fully integrated unit on 31 March 2026. Its oncology biosimilars include trastuzumab (Ogivri, FDA December 2017; EMA 12 December 2018, the first trastuzumab biosimilar in the US), bevacizumab (Abevmy, EMA 21 April 2021) and pegfilgrastim (Fulphila) for chemotherapy-induced neutropenia, alongside insulins and adalimumab. In May 2022 it bought the biosimilar assets of Viatris for 3.34 billion dollars, taking over the commercial infrastructure in the US and Europe. Domestically its CANMAb and Krabeva brands sit in the Indian market where several trastuzumab and bevacizumab biosimilars compete, which is why the reference brands cost a fraction of Western prices in India.
Headquarters
Bengaluru, IN
Scorecard
All companies#63of 1244 companies, score 64
- approved products +18
- targets +4
- modalities +2
- regions +8
- 24-month regulatory events +2
- registry trials +30
3 approved, 0 in phase 3, 0 earlier, 2 targets, 3,687 registry studies. Formula on the scorecards page.
Type
Website
Founded
2000
ApprovedBiosimilar monoclonal antibody (anti-HER2)
Trastuzumab biosimilars · Ogivri, Herzuma, Kanjinti, Trazimera, Ontruzant, Hercessi
Near-identical copies of Herceptin, approved since 2017, that cut the price of HER2 treatment and widened access worldwide.
ApprovedMonoclonal antibody (anti-HER2)
Trastuzumab · Herceptin (and biosimilars, Phesgo with pertuzumab)
The first targeted antibody for a solid tumour (1998), which turned HER2-positive breast cancer from the worst subtype into one of the most treatable.
ApprovedMonoclonal antibody (anti-VEGF)
Bevacizumab · Avastin (and biosimilars)
Bevacizumab is a humanised antibody that soaks up VEGF-A, the signal tumours use to grow new blood vessels. Approved in 2004, it partners chemotherapy in colorectal, ovarian, cervical, lung, kidney and liver cancer and glioblastoma, and adds to trifluridine/tipiracil in late-line bowel cancer; hypertension, protein in the urine and bleeding are its characteristic side effects.
Similar pages
- CompanyHetero Drugs
Shares Biosimilar, VEGF / VEGFR, Prices and value, Bevacizumab.
- IdeaMake the biosimilar the default at the pharmacy for trastuzumab, bevacizumab and rituximab
Shares Trastuzumab biosimilars, Biosimilar, Prices and value, Trastuzumab.
- IdeaWHO prequalification plus pooled demand to push biosimilar prices below 10% of the originator
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Trastuzumab, Most of the world has almost no cancer care.
- TermBiologics Price Competition and Innovation Act 2010
Shares Trastuzumab biosimilars, Biosimilar, Prices and value, Trastuzumab.
- IdeaTie WHO essential-medicines listing to a published tiered price and supply pledge
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Trastuzumab, Most of the world has almost no cancer care.
- IdeaBiosimilar-first defaults and payment parity in every cancer day unit
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Trastuzumab, Monoclonal antibodies.
- IdeaApprove cancer biosimilars on analytics and pharmacokinetics, no efficacy trials
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Trastuzumab, Monoclonal antibodies.
- TechnologyBiosimilar manufacturing and comparability
Shares Viatris, Biocon, Prices and value, Trastuzumab.
fronts
technologies
targets
drugs
ApprovedMonoclonal antibody (anti-VEGF)
Bevacizumab · Avastin (and biosimilars)
ApprovedMonoclonal antibody (anti-HER2)
Trastuzumab · Herceptin (and biosimilars, Phesgo with pertuzumab)
ApprovedBiosimilar monoclonal antibody (anti-HER2)
Trastuzumab biosimilars · Ogivri, Herzuma, Kanjinti, Trazimera, Ontruzant, Hercessi